Peptide receptor chemo-radionuclide therapy (PRCRT) in patients with well-differentiated GEP NETs treated within early-phase clinical trials provided ORRs as high as 24–53% [173,174,175], which also exceeded 80% in the subgroup of patients with pancreatic NETs receiving PRCRT with TEM—likely because of the role of MGMT (O(6)-methylguanine-DNA methyltransferase) promoter methylation in these patients [176]. The gene discussed is MGMT; the disease is pancreatic neuroendocrine tumor.